Clinical Trial Update: Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant Ivonescimab with chemotherapy for resectable esophageal squamous cell carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophageal Squamour Cell Cancer | Phase 2 | Status: NOT_YET_RECRUITING